Evidence is provided that in anaesthetized rabbits the atherogenic uptake of low-density lipoprotein (LDL) by arterial walls is accelerated by norepinephrine at its physiological concentrations in rabbit and human blood. The principle of the experiments was to compare the uptake of intravenously injected, radioactively labelled LDL, methylated to prevent removal by high-affinity receptors, in the two carotid arteries of anaesthetized rabbits after infusing low concentrations of norepinephrine noradrenaline into one carotid and saline as control into the other, the volume rates of infusion being about 1% of the carotid blood flows. The results thus obtained may contribute towards an explanation for the accelerated atherosclerosis and the increased incidence of its clinical manifestation in conditions associated with elevated blood norepinephrine concentrations, including the episodic increases associated with stress and cigarette smoking as well as the more persistent increases caused by phaeochromocytoma.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Zhilong Huoxue Tongyu capsule protects against atherosclerosis by suppressing EndMT via modulating Hippo/YAP signaling pathway.
J Tradit Complement Med
November 2024
National Traditional Chinese Medicine Clinical Research Base and Drug Research Center of Integrated Traditional Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan, China.
Background And Aim: Zhilong Huoxue Tongyu Capsule (ZL capsule) has been demonstrated to be an effective and widely-used traditional Chinese medicine (TCM) formula for the treatment of various diseases, especially for atherosclerosis (AS) related cardiovascular and cerebrovascular diseases. Reversal of endothelial-mesenchymal transition (EndMT) plays a crucial role in the cure of AS. But the curative impact of ZL capsule on EndMT remains obscure during the development of AS.
View Article and Find Full Text PDFExploring the alleviating effects of metabolite lactic acid on non-alcoholic steatohepatitis through the gut-liver axis.
Front Microbiol
January 2025
Department of Infectious Disease, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Objective: This study investigates the protective effects of lactic acid, a metabolite of , on non-alcoholic fatty liver disease (NAFLD) induced by a high-sugar, high-fat diet (HFD) in mice, in the context of the gut-liver axis.
Methods: A NAFLD mouse model was established using a HFD, and different intervention groups were set up to study the protective effects of and its metabolite lactic acid. The groups included a control group, NAFLD group, treatment group, Glyceraldehyde-3-P (G-3P) co-treatment group, and NOD-like receptor family pyrin domain containing 3 (NLRP3) overexpression group.
Sulforaphane alleviates membranous nephropathy by inhibiting oxidative stress-associated podocyte pyroptosis.
Iran J Basic Med Sci
January 2025
Department of Nephrology, Affiliated Hospital of Jiangnan University, Wuxi, China.
Objectives: To investigate the natural product sulforaphane (SFN) in protection of membranous nephropathy (MN) by inhibiting oxidative stress-associated podocyte pyroptosis.
Materials And Methods: A passive Heymann nephritis (PHN) model was established and treated with SFN. Clinical manifestations were examined by testing 24-hr urine protein, albumin, total cholesterol, triglyceride, high-density and low-density lipoprotein levels.
Lipid-Lowering Drugs and Pulmonary Vascular Disease: A Mendelian Randomization Study.
Pulm Circ
January 2025
Center of Gerontology and Geriatrics National Clinical Research Center for Geriatrics,West China Hospital, Sichuan University Chengdu China.
The therapeutic value of lipid-lowering drugs in pulmonary vascular disease remains uncertain due to insufficient studies and evidence. This study aims to investigate the causal effects of lipid-lowering drugs (specifically, inhibitors of APOB, CETP, HMGCR, NPC1L1, and PCSK9) on pulmonary vascular diseases using a Mendelian randomization (MR) approach. We utilized summary-level statistics from genome-wide association studies (GWAS) to simulate the exposure to low-density lipoprotein cholesterol (LDL-C) and its outcomes on pulmonary arterial hypertension (PAH), pulmonary embolism (PE), and pulmonary heart disease (PHD).
View Article and Find Full Text PDFLong-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B: Detailed Analysis of Treatment-Naive and Experienced Patients.
Korean J Gastroenterol
January 2025
Peking University People's Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China.
Background/aims: This study assessed the long-term efficacy and safety of tenofovir alafenamide (TAF) in real-world settings.
Methods: Patients who were candidates for TAF treatment and were followed up at 12-week intervals over 192 weeks were enrolled in this study.
Results: One hundred and forty-four patients (50 treatment-naive and 94 treatment-experienced) were included in this study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!